811 related articles for article (PubMed ID: 19559476)
1. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial.
Priotto G; Kasparian S; Mutombo W; Ngouama D; Ghorashian S; Arnold U; Ghabri S; Baudin E; Buard V; Kazadi-Kyanza S; Ilunga M; Mutangala W; Pohlig G; Schmid C; Karunakara U; Torreele E; Kande V
Lancet; 2009 Jul; 374(9683):56-64. PubMed ID: 19559476
[TBL] [Abstract][Full Text] [Related]
2. Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial.
Mesu VKBK; Kalonji WM; Bardonneau C; Mordt OV; Blesson S; Simon F; Delhomme S; Bernhard S; Kuziena W; Lubaki JF; Vuvu SL; Ngima PN; Mbembo HM; Ilunga M; Bonama AK; Heradi JA; Solomo JLL; Mandula G; Badibabi LK; Dama FR; Lukula PK; Tete DN; Lumbala C; Scherrer B; Strub-Wourgaft N; Tarral A
Lancet; 2018 Jan; 391(10116):144-154. PubMed ID: 29113731
[TBL] [Abstract][Full Text] [Related]
3. A multicentre, randomised, non-inferiority clinical trial comparing a nifurtimox-eflornithine combination to standard eflornithine monotherapy for late stage Trypanosoma brucei gambiense human African trypanosomiasis in Uganda.
Kansiime F; Adibaku S; Wamboga C; Idi F; Kato CD; Yamuah L; Vaillant M; Kioy D; Olliaro P; Matovu E
Parasit Vectors; 2018 Feb; 11(1):105. PubMed ID: 29471865
[TBL] [Abstract][Full Text] [Related]
4. Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo.
Priotto G; Kasparian S; Ngouama D; Ghorashian S; Arnold U; Ghabri S; Karunakara U
Clin Infect Dis; 2007 Dec; 45(11):1435-42. PubMed ID: 17990225
[TBL] [Abstract][Full Text] [Related]
5. Nifurtimox-eflornithine combination therapy for second-stage gambiense human African trypanosomiasis: Médecins Sans Frontières experience in the Democratic Republic of the Congo.
Alirol E; Schrumpf D; Amici Heradi J; Riedel A; de Patoul C; Quere M; Chappuis F
Clin Infect Dis; 2013 Jan; 56(2):195-203. PubMed ID: 23074318
[TBL] [Abstract][Full Text] [Related]
6. In-hospital safety in field conditions of nifurtimox eflornithine combination therapy (NECT) for T. b. gambiense sleeping sickness.
Schmid C; Kuemmerle A; Blum J; Ghabri S; Kande V; Mutombo W; Ilunga M; Lumpungu I; Mutanda S; Nganzobo P; Tete D; Mubwa N; Kisala M; Blesson S; Mordt OV
PLoS Negl Trop Dis; 2012; 6(11):e1920. PubMed ID: 23209861
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of Nifurtimox Eflornithine Combination Therapy (NECT) in T. b. gambiense second stage sleeping sickness patients in the Democratic Republic of Congo: Report from a field study.
Kuemmerle A; Schmid C; Bernhard S; Kande V; Mutombo W; Ilunga M; Lumpungu I; Mutanda S; Nganzobo P; Tete DN; Kisala M; Burri C; Blesson S; Valverde Mordt O
PLoS Negl Trop Dis; 2021 Nov; 15(11):e0009903. PubMed ID: 34748572
[TBL] [Abstract][Full Text] [Related]
8. Prescription of concomitant medications in patients treated with Nifurtimox Eflornithine Combination Therapy (NECT) for T.b. gambiense second stage sleeping sickness in the Democratic Republic of the Congo.
Kuemmerle A; Schmid C; Kande V; Mutombo W; Ilunga M; Lumpungu I; Mutanda S; Nganzobo P; Ngolo D; Kisala M; Valverde Mordt O
PLoS Negl Trop Dis; 2020 Jan; 14(1):e0008028. PubMed ID: 31986140
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by Trypanosoma brucei gambiense: a multicentre, open-label, single-arm, phase 2/3 trial.
Betu Kumeso VK; Kalonji WM; Rembry S; Valverde Mordt O; Ngolo Tete D; Prêtre A; Delhomme S; Ilunga Wa Kyhi M; Camara M; Catusse J; Schneitter S; Nusbaumer M; Mwamba Miaka E; Mahenzi Mbembo H; Makaya Mayawula J; Layba Camara M; Akwaso Massa F; Kaninda Badibabi L; Kasongo Bonama A; Kavunga Lukula P; Mutanda Kalonji S; Mariero Philemon P; Mokilifi Nganyonyi R; Embana Mankiara H; Asuka Akongo Nguba A; Kobo Muanza V; Mulenge Nasandhel E; Fifi Nzeza Bambuwu A; Scherrer B; Strub-Wourgaft N; Tarral A
Lancet Infect Dis; 2023 Apr; 23(4):463-470. PubMed ID: 36460027
[TBL] [Abstract][Full Text] [Related]
10. Mortality trends and risk factors in advanced stage-2 Human African Trypanosomiasis: A critical appraisal of 23 years of experience in the Democratic Republic of Congo.
Kazumba LM; Kaka JT; Ngoyi DM; Tshala-Katumbay D
PLoS Negl Trop Dis; 2018 Jun; 12(6):e0006504. PubMed ID: 29897919
[TBL] [Abstract][Full Text] [Related]
11. NECT trial: more than a small victory over sleeping sickness.
Opigo J; Woodrow C
Lancet; 2009 Jul; 374(9683):7-9. PubMed ID: 19559477
[No Abstract] [Full Text] [Related]
12. Equivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei gambiense sleeping sickness.
Bisser S; N'Siesi FX; Lejon V; Preux PM; Van Nieuwenhove S; Miaka Mia Bilenge C; Būscher P
J Infect Dis; 2007 Feb; 195(3):322-9. PubMed ID: 17205469
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy for second-stage human African trypanosomiasis: drugs in use.
Lutje V; Probyn K; Seixas J; Bergman H; Villanueva G
Cochrane Database Syst Rev; 2021 Dec; 12(12):CD015374. PubMed ID: 34882307
[TBL] [Abstract][Full Text] [Related]
14. Oral fexinidazole for stage 1 or early stage 2 African Trypanosoma brucei gambiense trypanosomiasis: a prospective, multicentre, open-label, cohort study.
Kande Betu Ku Mesu V; Mutombo Kalonji W; Bardonneau C; Valverde Mordt O; Ngolo Tete D; Blesson S; Simon F; Delhomme S; Bernhard S; Mahenzi Mbembo H; Mpia Moke C; Lumeya Vuvu S; Mudji E'kitiak J; Akwaso Masa F; Mukendi Ilunga M; Mpoyi Muamba Nzambi D; Mayala Malu T; Kapongo Tshilumbwa S; Botalema Bolengi F; Nkieri Matsho M; Lumbala C; Scherrer B; Strub-Wourgaft N; Tarral A
Lancet Glob Health; 2021 Jul; 9(7):e999-e1008. PubMed ID: 34143998
[TBL] [Abstract][Full Text] [Related]
15. Population Pharmacodynamic Modeling of Eflornithine-Based Treatments Against Late-Stage Gambiense Human African Trypanosomiasis and Efficacy Predictions of L-eflornithine-Based Therapy.
Amilon C; Boberg M; Tarning J; Äbelö A; Ashton M; Jansson-Löfmark R
AAPS J; 2022 Mar; 24(3):48. PubMed ID: 35338410
[TBL] [Abstract][Full Text] [Related]
16. Short-course eflornithine in Gambian trypanosomiasis: a multicentre randomized controlled trial.
Pépin J; Khonde N; Maiso F; Doua F; Jaffar S; Ngampo S; Mpia B; Mbulamberi D; Kuzoe F
Bull World Health Organ; 2000; 78(11):1284-95. PubMed ID: 11143188
[TBL] [Abstract][Full Text] [Related]
17. NECT is next: implementing the new drug combination therapy for Trypanosoma brucei gambiense sleeping sickness.
Yun O; Priotto G; Tong J; Flevaud L; Chappuis F
PLoS Negl Trop Dis; 2010 May; 4(5):e720. PubMed ID: 20520803
[No Abstract] [Full Text] [Related]
18. Chemotherapy for second-stage Human African trypanosomiasis.
Lutje V; Seixas J; Kennedy A
Cochrane Database Syst Rev; 2010 Aug; (8):CD006201. PubMed ID: 20687080
[TBL] [Abstract][Full Text] [Related]
19. Advances in sleeping sickness therapy.
Van Nieuwenhove S
Ann Soc Belg Med Trop; 1992; 72 Suppl 1():39-51. PubMed ID: 1417168
[TBL] [Abstract][Full Text] [Related]
20. High-dose nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness: an open trial in central Zaire.
Pépin J; Milord F; Meurice F; Ethier L; Loko L; Mpia B
Trans R Soc Trop Med Hyg; 1992; 86(3):254-6. PubMed ID: 1412646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
